FTSE 250 movers: Vistry surges, Syncona sinks on write-off

Shares in Vistry surged on Monday as the company said it planned to merge its housebuilding operations with the partnerships business by the end of the year as it also set new medium-term earnings targets.

The UK home builder on Monday said it was now aiming for return on capital employed of 40%, revenue growth of 5 – 8% a year and operating profit of £800m with an operating margin of at least 12%.

"The scale of the social need for affordable mixed tenure housing across the country continues to increase and it is clear that Vistry is uniquely positioned as the leader in partnerships housing," said chief executive Greg Fitzgerald.

Vistry posted an 8.4% fall in adjusted half-year pre-tax profits to £174m amid a tough housing market where prices have been falling in response to higher mortgage costs.

Half-year underlying revenue rose 31.4% to £1.8bn, while underlying operating profit was £206.7m, up 4.3%. Meanwhile Vistry's net debt position was £328.7m, compared to net cash of £118.2 at the end of last year, and the company maintained underlying pre-tax profit guidance for the full year of more than £450m.

"It's fair to say the housebuilding division’s been stuttering lately. Recent interest rate rises have reduced affordability for buyers, causing private sales rates to decline and completions to be wound lower as a result," said Aarin Chiekrie, equity analyst at Hargreaves Lansdown.

"That’s no surprise though, given housebuilding’s a notoriously cyclical sector. In contrast, Partnerships’ revenues tend to be more robust - the need for more affordable housing doesn’t go away because economic conditions look tough. This provides large fixed-volume projects which should hold up better in a downturn."

Syncona shares fell as the British healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, which would result in a milestone payments write-off of £54.5m for Gyroscope Holdings Limited in which Syncona had a 54% stake.

Gyroscope was sold to Novartis in February last year in a $1.5bn deal, with Syncona receiving $442m for its stake.

Market Movers

FTSE 250 (MCX) 18,501.26 0.21%

FTSE 250 - Risers

Vistry Group (VTY) 915.00p 14.38%
Babcock International Group (BAB) 396.60p 3.34%
Hipgnosis Songs Fund Limited NPV (SONG) 94.80p 2.71%
Petershill Partners (PHLL) 154.00p 2.67%
TUI AG Reg Shs (DI) (TUI) 476.80p 2.58%
Vanquis Banking Group 20 (VANQ) 120.00p 2.56%
Me Group International (MEGP) 161.00p 2.55%
Jupiter Fund Management (JUP) 95.85p 2.51%
Molten Ventures (GROW) 246.40p 2.24%
HGCapital Trust (HGT) 397.00p 2.06%

FTSE 250 - Fallers

Syncona Limited NPV (SYNC) 120.20p -6.09%
W.A.G Payment Solutions (WPS) 86.20p -5.27%
Direct Line Insurance Group (DLG) 175.45p -3.33%
Baltic Classifieds Group (BCG) 192.40p -3.02%
Wizz Air Holdings (WIZZ) 1,988.50p -2.72%
Playtech (PTEC) 517.50p -2.54%
NCC Group (NCC) 94.50p -2.07%
Indivior (INDV) 1,801.00p -1.91%
Senior (SNR) 172.60p -1.71%
Bakkavor Group (BAKK) 99.40p -1.58%